[{"orgOrder":0,"company":"Mirus Bio","sponsor":"Kytopen","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"Human Cellular Medicine","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Mirus Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Mirus Bio \/ Mirus Bio","highestDevelopmentStatusID":"1","companyTruncated":"Mirus Bio \/ Mirus Bio"}]

Find Clinical Drug Pipeline Developments & Deals by Mirus Bio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Kytopen and Mirus Bio will collaborate to combine industry-leading technologies and tackle the non-viral delivery of highly complex genome engineering materials to help create human cellular medicines.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          January 31, 2023

                          Lead Product(s) : Human Cellular Medicine

                          Therapeutic Area : Technology

                          Highest Development Status : Undisclosed

                          Recipient : Kytopen

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank